Francis Knuettel II, Chief Financial Officer of OS Therapies Inc, filed a Form 4 on October 30, 2026, disclosing the grant of 300,000 stock options on October 22, 2026, and an indirect holding of 20,000 shares of common stock through the Lara Knuettel Revocable Trust.

Key Highlights

  • Option grant: Knuettel received options to purchase 300,000 shares of OS Therapies common stock on October 22, 2026.
  • Exercise price: The options carry an exercise price of $1.25 per share, according to the filing.
  • Expiration date: The options expire on October 22, 2036.
  • Vesting schedule: The options vest in 12 equal monthly installments beginning on each monthly anniversary of the grant date, subject to continued employment.
  • Plan basis: The grant was made under OS Therapies' amended and restated 2023 incentive compensation plan.
  • Indirect share holding: The filing reports 20,000 shares of common stock held indirectly through the Lara Knuettel Revocable Trust, of which Knuettel is co-trustee.

Knuettel Option Grant and Beneficial Ownership Details at OS Therapies

According to the Form 4 filed with the SEC on October 30, 2026, Francis Knuettel II, the Chief Financial Officer of OS Therapies Inc (NASDAQ:OSTX), acquired stock options covering 300,000 shares of the company's common stock. The transaction date is listed as October 22, 2026, and the filing records the acquisition code as "A," indicating an award rather than an open-market purchase. The reported price of the derivative security is $0, consistent with a grant under a compensation plan.

The filing states that the options were granted "pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan." Vesting occurs in 12 equal installments on each monthly anniversary of the grant date, provided Knuettel is serving as an employee of OS Therapies on each applicable vesting date. Following this transaction, Knuettel beneficially owns 300,000 derivative securities directly.

In Table I of the filing, 20,000 shares of common stock are reported as indirectly owned through the Lara Knuettel Revocable Trust. No transaction code or price is associated with that entry, indicating it reflects a pre-existing holding. The filing notes that Knuettel "disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."

What Was Disclosed

The filing discloses a stock option award of 300,000 shares at $1.25 exercise price granted to OS Therapies' CFO on October 22, 2026, vesting monthly over 12 installments, plus an indirect holding of 20,000 common shares through a revocable trust.